Page last updated: 2024-12-09

n-benzoylalanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-benzoylalanine: RN given refers to parent cpd (L-Ala)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-benzoylalanine : An N-acylamino acid that is the N-benzoyl derivative of alanine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

N-benzoyl-L-alanine : An N-acyl-L-alanine resulting from the formal condensation of L-alanine with the carboxy group of benzoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID709778
CHEMBL ID291475
CHEBI ID71166
SCHEMBL ID698880
MeSH IDM0136449

Synonyms (41)

Synonym
AKOS015839077
n-benzoyl-l-alanine
2198-64-3
n-benzoylalanine
l-alanine, n-benzoyl-
chebi:71166 ,
CHEMBL291475
2-benzoylamino-propionic acid
(2s)-2-benzamidopropanoic acid
bzo-ala-oh
A815803
nsc 43124
einecs 218-601-3
hippuric acid, alpha-methyl-, (s)-
hippuric acid, alpha-methyl-
alanine, n-benzoyl-, l-
(s)-alpha-methylhippuric acid
bz-ala-oh
(2s)-2-(phenylformamido)propanoic acid
AB01115366-03
SCHEMBL698880
UAQVHNZEONHPQG-ZETCQYMHSA-N
n-benzoyl l-alanine
n-benzoyl-alanine
n-alpha-benzoyl-l-alanine (bz-l-ala-oh)
mfcd00063128
(s)-2-benzamidopropanoic acid
FD21045
benzoyl-l-alanine
DTXSID40176394
benzoylalanin
Z56889031
NCGC00329328-01
n-benzoyl alanine
AS-48940
Q26840895
CS-0117009
(2s)-2-(benzoylamino)propanoic acid
l-alanine,n-benzoyl-
EN300-898228
bz-l-ala-oh

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" After comparing the pharmacokinetic behavior of panipenem in patients with ESRD and that of a surrogate marker of efficacy, we recommend that these patients be treated with 500 mg/500 mg of panipenem/betamipron once daily, which gives a similar clinical result in a patient with normal renal function."( Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease.
Hishida, A; Kanamaru, M; Nagashima, S; Ohashi, N; Tajima, N; Togawa, A; Uematsu, T, 2005
)
0.33
"Population pharmacokinetic analyses were performed with plasma concentrations from 26 healthy volunteers and 41 patients."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" Because 30% of panipenem and most of the betamipron are excreted in the urine in an unchanged form, renal function is the important determinant of the dosage regimen of panipenem/betamipron."( Pharmacokinetics of panipenem/betamipron in patients with end-stage renal disease.
Hishida, A; Kanamaru, M; Nagashima, S; Ohashi, N; Tajima, N; Togawa, A; Uematsu, T, 2005
)
0.33
"Although plasma concentrations of panipenem were elevated and the risk of adverse events would increase in patients with renal impairment, a precise dosage regimen for patients with renal impairment has not been established."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.33
" Optimal dosage regimens for patients with renal impairment were determined based on the bacteriostatic index of C(20%T)>(MIC), the concentration corresponding to the time above MIC of 20% of the dosing interval."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.33
"The dosage regimen of panipenem for patients with renal impairment should be reduced when creatinine clearance is lower than 60 ml/min."( Population pharmacokinetic analysis of panipenem/betamipron in patients with various degrees of renal function.
Ishizuka, H; Naganuma, H; Tajima, N, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
N-benzoylalanineAn N-acylamino acid that is the N-benzoyl derivative of alanine.
N-acyl-L-alanineAn N-acyl-L-alpha-amino acid that is L-alanine in which a hydrogen attached to the nitrogen is replaced by an acyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID233318Bitter threshold value1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
AID26797Partition coefficient (logP)1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
Quantitative structure-activity relationships of the bitter thresholds of amino acids, peptides, and their derivatives.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.45)18.7374
1990's15 (48.39)18.2507
2000's10 (32.26)29.6817
2010's3 (9.68)24.3611
2020's1 (3.23)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 18.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index18.71 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index13.88 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (18.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (3.23%)5.53%
Reviews0 (0.00%)6.00%
Case Studies4 (12.90%)4.05%
Observational0 (0.00%)0.25%
Other26 (83.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]